How should a patient be switched from telmisartan 80 mg once daily to irbesartan 300 mg once daily, including contraindications and monitoring?

Switching from Telmisartan 80mg to Irbesartan 300mg

Both telmisartan 80mg and irbesartan 300mg represent the maximum target doses for their respective ARBs, making this a straightforward 1:1 substitution that can be performed immediately without titration. 1, 2

Direct Substitution Protocol

Stop telmisartan 80mg and start irbesartan 300mg the next day. No washout period, dose titration, or overlap is necessary. Both medications are once-daily ARBs with similar mechanisms of action (AT1 receptor blockade), and both doses represent equivalent maximum therapeutic targets according to ACC/AHA and ISH guidelines 1, 2, 3, 4.

Dosing Equivalence

The guideline-recommended target doses are:

• Telmisartan: 80mg once daily (maximum dose)
• Irbesartan: 300mg once daily (maximum dose)

These represent therapeutically equivalent maximum doses for blood pressure control and cardiovascular risk reduction 1, 2.

Key Contraindications to Check Before Switching

Before making this switch, verify the patient does NOT have:

• Pregnancy or planning pregnancy (both drugs cause fetal toxicity - Class D in 2nd/3rd trimester) 3, 4
• History of angioedema with ARBs (absolute contraindication)
• Bilateral renal artery stenosis (risk of acute renal failure)
• Concurrent use with aliskiren in diabetic patients (contraindicated combination) 2, 4
• Severe volume depletion or salt depletion - if present, use irbesartan 75mg initially, then uptitrate to 300mg 3

Monitoring Requirements

Initial Monitoring (First 1-2 Weeks)

• Blood pressure: Check within 1-2 weeks to ensure continued control
• Serum creatinine and potassium: Check within 1-2 weeks, especially if:
  • eGFR <60 mL/min/1.73m²
  • Concurrent diuretic use
  • Diabetes mellitus
  • Baseline potassium >4.5 mmol/L

Ongoing Monitoring

• Blood pressure: Target <130/80 mmHg per current guidelines; achieve within 3 months 2, 5, 6
• Renal function and electrolytes: Recheck at 3 months, then every 6-12 months if stable
• Watch for hyperkalemia: Hold irbesartan if K+ >5.5 mmol/L; reduce dose if K+ 5.0-5.5 mmol/L 7

Clinical Considerations

Why This Switch Might Be Made

Both drugs are clinically equivalent for hypertension, but specific scenarios favor irbesartan:

• Type 2 diabetes with nephropathy: Irbesartan 300mg has superior evidence for renoprotection (IDNT and IRMA-2 trials showed reduced progression to ESRD and proteinuria) 8, 3, 9
• Formulary/cost considerations: Insurance coverage differences
• Prior intolerance: Though both are well-tolerated, individual patient responses vary

Efficacy Expectations

Both medications provide 24-hour blood pressure control with once-daily dosing. Expect:

• Similar antihypertensive efficacy at these maximum doses 9, 10, 11
• Trough-to-peak ratio 60-70% for both drugs
• Full effect within 2 weeks, though some effect visible after first dose 3, 12

Safety Profile

Both drugs have placebo-like tolerability profiles:

• No increased cough (unlike ACE inhibitors) 9, 13
• No ankle edema (unlike calcium channel blockers)
• Similar adverse event rates to placebo in clinical trials 3, 9

Common Pitfalls to Avoid

1. Don't start at lower irbesartan doses (e.g., 150mg) unless the patient has volume depletion - you're switching from maximum-dose telmisartan, so use maximum-dose irbesartan 3

2. Don't combine with ACE inhibitors - dual RAS blockade increases risk of hyperkalemia, hypotension, and renal dysfunction without additional benefit 2, 6

3. Don't withhold in stable chronic kidney disease - ARBs are renoprotective in diabetic nephropathy and should be continued unless acute kidney injury develops 8, 3

4. Don't forget to counsel about pregnancy risk - both drugs must be discontinued immediately if pregnancy is detected 3, 4

Administration Details

• Take with or without food - no food effect on absorption 3
• Timing flexibility - can be taken at any time of day for patient convenience to improve adherence 6
• No rebound hypertension upon discontinuation 3